GlaxoSmithKline (GSK) Pharma said on May 5 that it has entered into a pact with Japan''s Astellas Pharma Inc for exclusive rights to sell the latter''s injectable anti-fungal agent Micafungin, branded Mycamine, in the local market. A product from Astellas'' research, Micafungin had got Japanese clearance in 2002. The partnership was in line with GSK Pharma''s strategy for growth in the local market and. Glenmark Pharmaceuticals Ltd said that it unveiled its topical antifungal cream Onabet (sertaconazole nitrate 2 per cent cream) in the domestic market.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment